Kevin Christian Montecillo Gulay

Kevin Christian Montecillo Gulay

Auto-generated profile, based on publicly available information

Kevin Christian Montecillo Gulay

Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
KGKevin Christian Montecillo. Gulay
Kevin Christian Montecillo. Gulay
XZXinlian Zhang
Xinlian Zhang
VPVasiliki Pantazopoulou
Vasiliki Pantazopoulou
JPJay Patel
Jay Patel
EEEdgar Esparza
Edgar Esparza
HTHervé Tiriac
Hervé Tiriac
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a low survival rate. Recently, new drugs that target KRASG12D, a common mutation in PDAC, have been developed. We studied one of these compounds, MRTX1133, and found it was specific and effective at low nanomolar concentrations in patient-derived organoid models and cell lines harboring KRASG12D mutations. Treatment with MRTX1133 upregulated the expression and phosphorylation of EGFR and HER2, indicating that inhibition of ERBB signaling may potentiate MRTX1133 antitumor activity. Indeed, the irreversible pan-ERBB inhibitor, afatinib, potently synergized with MRTX1133 in vitro, and cancer cells with acquired resistance to MRTX1133 in vitro remained sensitive to this combination therapy. Finally, the combination of MRTX1133 and afatinib led to tumor regression and longer survival in orthotopic PDAC mouse models. These results suggest that dual inhibition of ERBB and KRAS signaling may be synergistic and circumvent the rapid development of acquired resistance in patients with KRAS mutant pancreatic cancer. Significance: KRAS-mutant pancreatic cancer models, including KRAS inhibitor–resistant models, show exquisite sensitivity to combined pan-ERBB and KRAS targeting, which provides the rationale for testing this drug combination in clinical trials.

1 July 2021 in Journal of Genetics and Genomics
Verified
Journal Article
Closed access
KGKevin Christian Montecillo Gulay
Kevin Christian Montecillo Gulay
KAKeisuke Aoshima
Keisuke Aoshima
YSYuki Shibata
Yuki Shibata
HYHironobu Yasui
Hironobu Yasui
Qin YanQin Yan
Qin Yan
TKTakashi Kimura
Takashi Kimura

2 January 2025 in Cancer Research
Verified
Journal Article
Open access
PDF file
BGBharti Garg
Bharti Garg
SKSohini Khan
Sohini Khan
ACAsimina S. Courelli
Asimina S. Courelli
PPPonmathi Panneerpandian
Ponmathi Panneerpandian
DBDeepa Sheik Pran Babu
Deepa Sheik Pran Babu
ALAndrew M Lowy
Andrew M Lowy
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers; thus, identifying more effective therapies is a major unmet need. In this study, we characterized the super-enhancer (SE) landscape of human PDAC to identify drivers of the disease that might be targetable. This analysis revealed MICAL2 as an SE-associated gene in human PDAC, which encodes the flavin monooxygenase enzyme that induces actin depolymerization and indirectly promotes serum response factor transcription by modulating the availability of serum response factor coactivators such as myocardin-related transcription factors (MRTF-A and MRTF-B). MICAL2 was overexpressed in PDAC, and high-MICAL2 expression correlated with poor patient prognosis. Transcriptional analysis revealed that MICAL2 upregulates KRAS and epithelial–mesenchymal transition signaling pathways, contributing to tumor growth and metastasis. In loss- and gain-of-function experiments in human and mouse PDAC cells, MICAL2 promoted both ERK1/2 and AKT activation. Consistent with its role in actin depolymerization and KRAS signaling, loss of MICAL2 also inhibited macropinocytosis. MICAL2, MRTF-A, and MRTF-B influenced PDAC cell proliferation and migration and promoted cell-cycle progression in vitro. Importantly, MICAL2 supported in vivo tumor growth and metastasis. Interestingly, MRTF-B, but not MRTF-A, phenocopied MICAL2-driven phenotypes in vivo. This study highlights the multiple ways in which MICAL2 affects PDAC biology and provides a foundation for future investigations into the potential of targeting MICAL2 for therapeutic intervention. Significance: Characterization of the epigenomic landscape of pancreatic cancer to identify early drivers of tumorigenesis uncovered MICAL2 as a super-enhancer–associated gene critical for tumor progression that represents a potential pharmacologic target.

1 August 2021 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
KGKevin Christian Montecillo Gulay
Kevin Christian Montecillo Gulay
NNNoriyuki Nagata
Noriyuki Nagata
KAKeisuke Aoshima
Keisuke Aoshima
NSNozomi Shiohara
Nozomi Shiohara
AKAtsushi Kobayashi
Atsushi Kobayashi
TKTakashi Kimura
Takashi Kimura

17 June 2026
Verified
Other
Open access
BGBharti Garg
Bharti Garg
SKSohini Khan
Sohini Khan
ACAsimina S. Courelli
Asimina S. Courelli
PPPonmathi Panneerpandian
Ponmathi Panneerpandian
DBDeepa Sheik Pran Babu
Deepa Sheik Pran Babu
ALAndrew M Lowy
Andrew M Lowy

17 June 2026
Verified
Other
Open access
KGKevin Christian Montecillo Gulay
Kevin Christian Montecillo Gulay
XZXinlian Zhang
Xinlian Zhang
VPVasiliki Pantazopoulou
Vasiliki Pantazopoulou
JPJay Patel
Jay Patel
EEEdgar Esparza
Edgar Esparza
HTHervé Tiriac
Hervé Tiriac
Supplemental Figure and Table Legends